Search

Your search keyword '"W. Hinkelbein"' showing total 214 results
Start Over Author "W. Hinkelbein"
214 results on '"W. Hinkelbein"'

2. [Not Available]

Author

Thomas G, Wendt, G, Gademann, C, Pambor, I, Grießbach, H, von Specht, T, Martin, D, Baltas, R, Kurek, S, Röddiger, U W, Tunn, N, Zamboglou, H T, Eich, S, Staar, A, Gossmann, K, Hansemann, R, Semrau, R, Skripnitchenko, V, Diehl, R-P, Müller, S, Sehlen, N, Willich, U, Rühl, P, Lukas, E, Dühmke, K, Engel, E, Tabbert, M, Bolck, S, Knaack, H, Annweiler, R, Krempien, H, Hoppe, W, Harms, S, Daeuber, O, Schorr, M, Treiber, J, Debus, M, Alber, F, Paulsen, M, Birkner, A, Bakai, C, Belka, W, Budach, K-H, Grosser, R, Kramer, B, Kober, M, Reinert, P, Schneider, A, Hertel, H, Feldmann, P, Csere, C, Hoinkis, G, Rothe, P, Zahn, H, Alheit, S X, Cavanaugh, P, Kupelian, C, Reddy, B, Pollock, M, Fuss, S, Roeddiger, T, Dannenberg, B, Rogge, D, Drechsler, T, Herrmann, W, Alberti, R, Schwarz, M, Graefen, A, Krüll, V, Rudat, H, Huland, C, Fehr, C, Baum, S, Glocker, F, Nüsslin, T, Heil, H, Lemnitzer, M, Knips, O, Baumgart, W, Thiem, K-H, Kloetzer, L, Hoffmann, B, Neu, B, Hültenschmidt, M-L, Sautter-Bihl, O, Micke, M H, Seegenschmiedt, D, Köppen, G, Klautke, R, Fietkau, J, Schultze, G, Schlichting, H, Koltze, B, Kimmig, M, Glatzel, D, Fröhlich, S, Bäsecke, A, Krauß, D, Strauß, K-J, Buth, R, Böhme, W, Oehler, D, Bottke, U, Keilholz, K, Heufelder, T, Wiegel, W, Hinkelbein, C, Rödel, T, Papadopoulos, M, Munnes, R, Wirtz, R, Sauer, F, Rödel, D, Lubgan, L, Distel, G G, Grabenbauer, A, Sak, G, Stüben, C, Pöttgen, S, Grehl, M, Stuschke, K, Müller, C, Pfaffendorf, A, Mayerhofer, F M, Köhn, J, Ring, D, van Beuningen, V, Meineke, S, Neubauer, U, Keller, M, Wittlinger, D, Riesenbeck, B, Greve, R, Exeler, M, Ibrahim, C, Liebscher, E, Severin, O, Ott, R, Pötter, J, Hammer, G, Hildebrandt, M W, Beckmann, V, Strnad, F, Fehlauer, S, Tribius, A, Bajrovic, U, Höller, D, Rades, A, Warszawski, R, Baumann, B, Madry-Gevecke, J H, Karstens, C, Grehn, F, Hensley, C, Berns, M, Wannenmacher, S, Semrau, T, Reimer, B, Gerber, P, Ketterer, E, Koepcke, G, Hänsgen, H G, Strauß, J, Dunst, J, Füller, S, Kalb, T, Wendt, H D, Weitmann, C, Waldhäusl, T-H, Knocke, U, Lamprecht, J, Classen, T W, Kaulich, B, Aydeniz, M, Bamberg, T, Wiezorek, N, Banz, H, Salz, M, Scheithauer, M, Schwedas, J, Lutterbach, S, Bartelt, H, Frommhold, J, Lambert, D, Hornung, S, Swiderski, M, Walke, A, Siefert, B, Pöllinger, K, Krimmel, M, Schaffer, O, Koelbl, K, Bratengeier, D, Vordermark, M, Flentje, B, Hero, F, Berthold, S E, Combs, S, Gutwein, D, Schulz-Ertner, M, van Kampen, C, Thilmann, M, Kocher, S, Kunze, S, Schild, K, Ikezaki, B, Müller, R, Sieber, C, Weiß, I, Wolf, F, Wenz, K-J, Weber, J, Schäfer, A, Engling, S, Laufs, M R, Veldwijk, D, Milanovic, K, Fleckenstein, W, Zeller, S, Fruehauf, C, Herskind, M, Weinmann, V, Jendrossek, C, Rübe, S, Appold, S, Kusche, T, Hölscher, K, Brüchner, P, Geyer, M, Baumann, R, Kumpf, F, Zimmermann, S, Schill, H, Geinitz, C, Nieder, B, Jeremic, M, Molls, S, Liesenfeld, H, Petrat, S, Hesselmann, U, Schäfer, F, Bruns, E, Horst, R, Wilkowski, G, Assmann, A, Nolte, J, Diebold, U, Löhrs, P, Fritz, K, Hans-Jürgen, W, Mühlnickel, P, Bach, B, Wahlers, H-J, Kraus, J, Wulf, U, Hädinger, K, Baier, T, Krieger, G, Müller, H, Hof, K, Herfarth, T, Brunner, S M, Hahn, F S, Schreiber, A K, Rustgi, W G, McKenna, E J, Bernhard, M, Guckenberger, K, Meyer, J, Willner, M, Schmidt, M, Kolb, M, Li, P, Gong, A, Abdollahi, T, Trinh, P E, Huber, H, Christiansen, B, Saile, K, Neubauer-Saile, S, Tippelt, M, Rave-Fränk, R M, Hermann, J, Dudas, C F, Hess, H, Schmidberger, G, Ramadori, N, Andratschke, R, Price, K-K, Ang, S, Schwarz, U, Kulka, M, Busch, L, Schlenger, J, Bohsung, I, Eichwurzel, G, Matnjani, D, Sandrock, M, Richter, R, Wurm, V, Budach, A, Feussner, J, Gellermann, A, Jordan, R, Scholz, U, Gneveckow, K, Maier-Hauff, R, Ullrich, P, Wust, R, Felix, N, Waldöfner, M, Seebass, H-J, Ochel, A, Dani, A, Varkonyi, M, Osvath, A, Szasz, P M, Messer, N M, Blumstein, H-W, Gottfried, E, Schneider, S N, Reske, E M, Röttinger, A-L, Grosu, M, Franz, S, Stärk, W, Weber, M, Heintz, F, Indenkämpen, T, Beyer, W, Lübcke, S, Levegrün, J, Hayen, N, Czech, B, Mbarek, R, Köster, H, Thurmann, M, Todorovic, A, Schuchert, T, Meinertz, T, Münzel, H, Grundtke, B, Hornig, T, Hehr, C, Dilcher, R C, Chan, G S, Mintz, J-I, Kotani, V M, Shah, D A, Canos, N J, Weissman, R, Waksman, R, Wolfram, B, Bürger, M, Schrappe, B, Timmermann, A, Lomax, G, Goitein, A, Schuck, A, Mattke, C, Int-Veen, I, Brecht, S, Bernhard, J, Treuner, E, Koscielniak, F, Heinze, M, Kuhlen, I, von Schorlemer, S, Ahrens, A, Hunold, S, Könemann, W, Winkelmann, H, Jürgens, J, Gerstein, B, Polivka, K-W, Sykora, M, Bremer, R, Thamm, C, Höpfner, H, Gumprecht, R, Jäger, M A, Leonardi, A M, Frank, A E, Trappe, C B, Lumenta, E, Östreicher, K, Pinsker, A, Müller, C, Fauser, W, Arnold, M, Henzel, M W, Groß, R, Engenhart-Cabillic, P, Schüller, S, Palkovic, J, Schröder, H, Wassmann, A, Block, R, Bauer, F-W, Keffel, B, Theophil, L, Wisser, M, Rogger, M, Niewald, V, van Lengen, K, Mathias, G, Welzel, M, Bohrer, S, Steinvorth, C, Schleußner, K, Leppert, B, Röhrig, B, Strauß, B, van Oorschot, N, Köhler, R, Anselm, A, Winzer, T, Schneider, U, Koch, K, Schönekaes, R, Mücke, J, Büntzel, K, Kisters, C, Scholz, M, Keller, C, Winkler, N, Prause, R, Busch, S, Roth, I, Haas, R, Willers, S, Schultze-Mosgau, J, Wiltfang, P, Kessler, F W, Neukam, B, Röper, N, Nüse, F, Auer, W, Melzner, M, Geiger, M, Lotter, T, Kuhnt, A C, Müller, N, Jirsak, C, Gernhardt, H-G, Schaller, B, Al-Nawas, M O, Klein, C, Ludwig, J, Körholz, K A, Grötz, K, Huppers, M, Kunkel, T, Olschewski, K, Bajor, B, Lang, E, Lang, U, Kraus-Tiefenbacher, R, Hofheinz, B, von Gerstenberg-Helldorf, F, Willeke, A, Hochhaus, M, Roebel, S, Oertel, S, Riedl, M, Buechler, T, Foitzik, K, Ludwig, E, Klar, A, Meyer, J, Meier Zu Eissen, D, Schwab, T, Meyer, S, Höcht, A, Siegmann, F, Sieker, S, Pigorsch, B, Milicic, L, Acimovic, S, Milisavljevic, G, Radosavljevic-Asic, N, Presselt, R P, Baum, D, Treutler, R, Bonnet, M, Schmücking, D, Sammour, T, Fink, J, Ficker, O, Pradier, K, Lederer, E, Weiss, A, Hille, S, Welz, S, Sepe, G, Friedel, W, Spengler, E, Susanne, O, Kölbl, W, Hoffmann, B, Wörmann, A, Günther, M, Becker-Schiebe, J, Güttler, C, Schul, M, Nitsche, M K, Körner, R, Oppenkowski, F, Guntrum, L, Malaimare, M, Raub, C, Schöfl, T, Averbeck, I, Hacker, H, Blank, C, Böhme, D, Imhoff, K, Eberlein, S, Weidauer, H D, Böttcher, L, Edler, M, Tatagiba, H, Molina, C, Ostertag, S, Milker-Zabel, A, Zabel, W, Schlegel, A, Hartmann, I, Wildfang, G, Kleinert, K, Hamm, W, Reuschel, R, Wehrmann, P, Kneschaurek, M W, Münter, A, Nikoghosyan, B, Didinger, S, Nill, B, Rhein, D, Küstner, U, Schalldach, D, Eßer, H, Göbel, H, Wördehoff, S, Pachmann, H, Hollenhorst, K, Dederer, C, Evers, J, Lamprecht, A, Dastbaz, B, Schick, J, Fleckenstein, P K, Plinkert, Chr, Rübe, T, Merz, B, Sommer, A, Mencl, V, Ghilescu, S, Astner, A, Martin, F, Momm, N J, Volegova-Neher, J, Schulte-Mönting, R, Guttenberger, A, Buchali, E, Blank, D, Sidow, W, Huhnt, T, Gorbatov, A, Heinecke, G, Beckmann, A-M, Bentia, H, Schmitz, U, Spahn, V, Heyl, P-J, Prott, R, Galalae, R, Schneider, C, Voith, A, Scheda, B, Hermann, L, Bauer, F, Melchert, N, Kröger, A, Grüneisen, F, Jänicke, A, Zander, I, Zuna, I, Schlöcker, K, Wagner, E, John, T, Dörk, G, Lochhas, M, Houf, D, Lorenz, K-H, Link, F-J, Prott, M, Thoma, R, Schauer, V, Heinemann, M, Romano, M, Reiner, A, Quanz, U, Oppitz, R, Bahrehmand, M, Tine, A, Naszaly, P, Patonay, Á, Mayer, K, Markert, S-K, Mai, F, Lohr, B, Dobler, M, Pinkawa, K, Fischedick, P, Treusacher, D, Cengiz, R, Mager, H, Borchers, G, Jakse, M J, Eble, B, Asadpour, B, Krenkel, R, Holy, Y, Kaplan, T, Block, H, Czempiel, U, Haverkamp, B, Prümer, T, Christian, P, Benkel, C, Weber, S, Gruber, P, Reimann, J, Blumberg, K, Krause, A-R, Fischedick, K, Kaube, K, Steckler, B, Henzel, N, Licht, T, Loch, A, Krystek, A, Lilienthal, H, Alfia, J, Claßen, P, Spillner, B, Knutzen, R, Souchon, I, Schulz, K, Grüschow, U, Küchenmeister, H, Vogel, D, Wolff, U, Ramm, J, Licner, F, Rudolf, J, Moog, C G, Rahl, S, Mose, H, Vorwerk, E, Weiß, A, Engert, I, Seufert, F, Schwab, J, Dahlke, T, Zabelina, W, Krüger, H, Kabisch, V, Platz, J, Wolf, B, Pfistner, B, Stieltjes, T, Wilhelm, M, Schmuecking, K, Junker, D, Treutier, C P, Schneider, J, Leonhardi, A, Niesen, K, Hoeffken, A, Schmidt, K-M, Mueller, I, Schmid, K, Lehmann, C G, Blumstein, R, Kreienberg, L, Freudenberg, H, Kühl, M, Stahl, B, Elo, P, Erichsen, H, Stattaus, T, Welzel, U, Mende, S, Heiland, B J, Salter, R, Schmid, D, Stratakis, R M, Huber, J, Haferanke, N, Zöller, M, Henke, J, Lorenzen, B, Grzyska, A, Kuhlmey, G, Adam, V, Hamelmann, T, Bölling, H, Job, J E, Panke, P, Feyer, S, Püttmann, B, Siekmeyer, H, Jung, B, Gagel, U, Militz, M, Piroth, A, Schmachtenberg, T, Hoelscher, C, Verfaillie, B, Kaminski, E, Lücke, H, Mörtel, W, Eyrich, M, Fritsch, J-C, Georgi, C, Plathow, H, Zieher, F, Kiessling, P, Peschke, H-U, Kauczor, J, Licher, O, Schneider, R, Henschler, C, Seidel, A, Kolkmeyer, T P, Nguyen, K, Janke, M, Michaelis, M, Bischof, C, Stoffregen, K, Lipson, K, Weber, V, Ehemann, D, Jürgen, P, Achanta, K, Thompson, J L, Martinez, T, Körschgen, R, Pakala, E, Pinnow, D, Hellinga, F, O'Tio, A, Katzer, A, Kaffer, A, Kuechler, S, Steinkirchner, N, Dettmar, N, Cordes, S, Frick, M, Kappler, H, Taubert, F, Bartel, H, Schmidt, M, Bache, S, Frühauf, T, Wenk, K, Litzenberger, M, Erren, F, van Valen, L, Liu, K, Yang, J, Palm, M, Püsken, M, Behe, T M, Behr, P, Marini, A, Johne, U, Claussen, T, Liehr, V, Steil, C, Moustakis, I, Griessbach, A, Oettel, C, Schaal, M, Reinhold, G, Strasssmann, I, Braun, P, Vacha, D, Richter, T, Osterham, P, Wolf, G, Guenther, M, Miemietz, E A, Lazaridis, B, Forthuber, M, Sure, J, Klein, H, Saleske, T, Riedel, P, Hirnle, G, Horstmann, H, Schoepgens, A, Van Eck, O, Bundschuh, A, Van Oosterhut, K, Xydis, K, Theodorou, C, Kappas, J, Zurheide, N, Fridtjof, U, Ganswindt, N, Weidner, M, Buchgeister, B, Weigel, S B, Müller, M, Glashörster, C, Weining, B, Hentschel, O A, Sauer, W, Kleen, J, Beck, D, Lehmann, S, Ley, C, Fink, M, Puderbach, W, Hosch, A, Schmähl, K, Jung, A, Stoßberg, E, Rolf, M, Damrau, D, Oetzel, U, Maurer, G, Maurer, K, Lang, J, Zumbe, D, Hahm, H, Fees, B, Robrandt, U, Melcher, M, Niemeyer, A, Mondry, V, Kanellopoulos-Niemeyer, H, Karle, D, Jacob-Heutmann, C, Born, W, Mohr, J, Kutzner, M, Thelen, M, Schiebe, U, Pinkert, L, Piasswilm, F, Pohl, S, Garbe, K, Wolf, Y, Nour, P, Barwig, D, Trog, C, Schäfer, M, Herbst, B, Dietl, M, Cartes, F, Schroeder, G, Sigingan-Tek, R, Feierabend, S, Theden, A, Schlieck, M, Gotthardt, U, Glowalla, S, Kremp, O, Hamid, N, Riefenstahl, B, Michaelis, G, Schaal, E, Liebermeister, U, Niewöhner-Desbordes, M, Kowalski, N, Franz, W, Stahl, C, Baumbach, J, Thale, W, Wagner, B, Justus, A L, Huston, R, Seaborn, P, Rai, S-W, Rha, G, Sakas, S, Wesarg, P, Zogal, B, Schwald, H, Seibert, R, Berndt-Skorka, G, Seifert, K, Schoenekaes, C, Bilecen, W, Ito, G, Matschuck, and D, Isik

Published
2016

3. Radiotherapy of Ocular Disease / Contents / Preface

Author

N. Bornfeld, W. Hinkelbein, T. Wiegel, and M.H. Foerster

Subjects
Radiation therapy, medicine.medical_specialty, business.industry, medicine.medical_treatment, medicine, Radiology, Ocular disease, business
Published
2015

4. Author Index / Subject Index

Author

M.H. Foerster, N. Bornfeld, W. Hinkelbein, and T. Wiegel

Subjects
Index (economics), Statistics, Subject (documents), Mathematics
Published
2015

5. Uterus Necrosis after Radiochemotherapy for Locally Advanced Cervical Cancer - A Case Report

Author

W. Hinkelbein, Christhardt Köhler, Simone Marnitz, and Achim Schneider

Subjects
Cervical cancer, medicine.medical_specialty, Hysterectomy, business.industry, medicine.medical_treatment, Pelvic pain, Brachytherapy, Obstetrics and Gynecology, medicine.disease, Surgery, Radiation therapy, medicine.anatomical_structure, Maternity and Midwifery, medicine, External beam radiotherapy, medicine.symptom, business, Cervix, Chemoradiotherapy
Abstract

Background: Simultaneous platin-based radiochemotherapy is the standard treatment for patients with advanced or nodal positive cancer of the uterine cervix. There is a large body of literature on therapy-related acute and late morbidity. Chemoradiation-associated necrosis of the uterus has not been described so far. Material, Methods and Results: We report on a patient who was treated by combined chemoradiation for histologically confirmed cervical cancer following laparoscopic staging. The patient was diagnosed with squamous cell cancer of the cervix FIGO IIIA (T3a pN1 MO G2). External beam radiotherapy was applied using a 3-D-planned four-field technique, covering the pelvic lymph nodes and the primary tumour. The patient was given brachytherapy (single dosis of 5 Gy, covering the tumour, total dose 25 Gy). Cisplatin was simultaneously administered. Following chemoradiation the patient developed pelvic pain and an elevation of CRP in the presence of a normal leukocyte count. On MRI, recurrence was suspected. The patient underwent re-laparoscopy and necrosis of the uterus was diagnosed without any evidence of recurrence. Laparoscopic assisted hysterectomy with bilateral salpingoophorectomy was performed. Conclusion: In patients with persistent or incident pelvic pain, questionable findings in imaging techniques and/or elevated inflammation parameters following completion of chemoradiation for cervical cancer differential diagnosis should include examination for radiogenic necrosis of the uterus and other pelvic organs. Laparoscopy is an ideal technique to exclude or confirm this diagnosis.

Published
2005

6. Spinales Kompressionssyndrom

Author

S. Hammersen, W. Hinkelbein, S. Hcht, and D. Bottke

Subjects
Oncology, business.industry, Spinal cord compression, Medicine, Hematology, Anatomy, business, medicine.disease
Published
2004

7. Mammatumoren / Tumours of the Mammary : Spezielle Strahlentherapie Maligner Tumoren Teil 2 / Radiation Therapy of Malignant Tumours Part 2

Author

R. Amalric, V. Barth, K.W. Brunner, F.C.H. Chu, O. Fischedick, H.-J. Frischbier, W. Hellriegel, W. Hinkelbein, J. Huys, S. Kaae, F. de Laender, H.v. Lieven, R. Monteyne, K. Prechtel, A. de Schryver, J.M. Spitalier, J.M. Vaeth, M. Wannenmacher, R. Amalric, V. Barth, K.W. Brunner, F.C.H. Chu, O. Fischedick, H.-J. Frischbier, W. Hellriegel, W. Hinkelbein, J. Huys, S. Kaae, F. de Laender, H.v. Lieven, R. Monteyne, K. Prechtel, A. de Schryver, J.M. Spitalier, J.M. Vaeth, and M. Wannenmacher

Subjects
Radiology, Gynecology
Published
2013

8. Band 25, Heft 3, Juni 2002

Author

J. Gellrich, M. Schostak, D.-C. Fischer, G. Hartung, A. Lossnitzer, T. Wiegel, T.G. Wendt, J. Pont, D.K. Bartsch, W. Queisser, J. Schmidt, M. Hudec, B.H. Didinger, M.P. Wirth, B. Gerdes, J. Sturm, J. Wagner, H.-J. Schmoll, P. Bank, W. Hinkelbein, S. Post, H. Rieder, T. Eberl, W. Budach, O.W. Hakenberg, M. Sina-Frey, S. Samel, D.G. Kieback, G. Postner, A. Manseck, R. Hehlmann, R. Brinkmann, H. Kienzer, Ch. Rübe, C. Dittrich, A. Hochhaus, B. Gabriel, U. Pichlmeier, R.-D. Hofheinz, M. Colombo Benkmann, M. Lörken, T.P. Nguyen, W. Schlegel, H. Gadner, R. Naumann, E. Przypadlo, R. Hofheinz, S. Höcht, J. Debus, R. Grützmann, R. Kress, S.A. Hahn, M. Baur, M. DeSantis, and A. Ziegler

Subjects
Cancer Research, Oncology, business.industry, Medicine, Hematology, business
Published
2002

9. Gastrointestinale Tumoren: Irinotecan erhöht die Chance, länger und besser zu überleben. Ergebnisse aus aktuellen klinischen Prüfungen. Clinical Investigators Update Meeting on Gastro-Intestinal Cancer, Sardinien, 20. April 2002

Author

O.W. Hakenberg, S. Höcht, D.G. Kieback, M. Baur, R. Hofheinz, J. Schmidt, W. Budach, A. Lossnitzer, H.-J. Schmoll, B. Gerdes, E. Przypadlo, R. Hehlmann, W. Hinkelbein, R. Brinkmann, C. Dittrich, B. Gabriel, M.P. Wirth, P. Bank, A. Hochhaus, M. Schostak, U. Pichlmeier, D.-C. Fischer, T. Eberl, J. Debus, R. Grützmann, M. Hudec, A. Ziegler, J. Pont, M. Lörken, G. Hartung, T.P. Nguyen, S. Samel, H. Gadner, G. Postner, B.H. Didinger, R. Naumann, T. Wiegel, D.K. Bartsch, Ch. Rübe, H. Rieder, J. Gellrich, J. Sturm, M. Colombo Benkmann, W. Queisser, S. Post, R.-D. Hofheinz, S.A. Hahn, W. Schlegel, A. Manseck, H. Kienzer, M. Sina-Frey, T.G. Wendt, R. Kress, M. DeSantis, and J. Wagner

Subjects
Cancer Research, Oncology, Hematology
Published
2002

10. Auf dem Weg zu kurativen Therapien beim multiplen Myelom? Expertenworkshop zu aktuellen Standards und neuen Entwicklungen

Author

R. Hehlmann, M. Baur, Ch. Rübe, M. Sina-Frey, J. Wagner, M. Hudec, A. Hochhaus, A. Lossnitzer, U. Pichlmeier, R. Brinkmann, S. Höcht, M. Colombo Benkmann, H. Rieder, B. Gabriel, G. Hartung, E. Przypadlo, R. Kress, T. Wiegel, W. Schlegel, W. Budach, B.H. Didinger, J. Sturm, C. Dittrich, M. DeSantis, D.K. Bartsch, S. Post, M. Schostak, D.-C. Fischer, W. Queisser, A. Manseck, M. Lörken, T.P. Nguyen, O.W. Hakenberg, H. Gadner, J. Pont, A. Ziegler, R. Naumann, H. Kienzer, D.G. Kieback, T.G. Wendt, G. Postner, T. Eberl, J. Gellrich, J. Schmidt, S. Samel, H.-J. Schmoll, B. Gerdes, W. Hinkelbein, J. Debus, R. Grützmann, S.A. Hahn, R. Hofheinz, R.-D. Hofheinz, M.P. Wirth, and P. Bank

Subjects
Cancer Research, Oncology, Hematology
Published
2002

12. Bendamustin. Neue Wege bei Lymphomen und soliden Tumoren. Bendamustin-Workshop, Dresden, 2. September 2000

Author

D. Bottke, S. Pampallona, G. Schaller, H. Schulz, E. von Rohr, S. Schwartz, A. Franke, I. Olkin, N. Bornfeld, T. Wiegel, M. Fuchs, K. Dietzmann, K. Mross, A. Engert, A. Schulz, E. Dühmke, W. Gesierich, C. Kahl, A. Florschütz, S. Krege, C. Bausewein, D. Söhngen, S. Helwig, V. Diehl, U. Aydemir, D.K. Ackermann, H.-J. Schmoll, R. Song, D. Moher, S.M. Liesenfeld, T. Cerny, S. Sehlen, T.G. Wendt, K. Jentsch-Ullrich, M. Groettrup, W. Hinkelbein, U. Geiersberger, A. Krackhardt, C. Hürny, R. Souchon, K.-M. Kreusel, R. Hartenstein, N. Brack, S. Eastwood, D. Rennie, N. v. Steinbüchel, D.J. Cook, B. van Wegberg, B. Schymura, A. Pfleiderer, P. Robben-Bathe, L. Edler, C. Unger, H. Pohlmann, R. Abelius, P. Heusser, J.O. Staak, T. Kühn, J. Bernhard, J. Baumgart, R. Munker, R. Kreienberg, D.F. Stroup, H. Hollenhorst, H. Fiebig, C. Scheid, E. Thiel, U. Winkler, W.E. Berdel, J. Dannull, and P. Sevelda

Subjects
Cancer Research, Oncology, Hematology
Published
2000

13. Complete Contents Vol. 23, 2000 / Jahresinhalt Band 23, 2000

Author

T. Wiegel, A. Schulz, R. Song, A. Krackhardt, R. Hartenstein, S. Eastwood, D. Bottke, H. Schulz, S. Pampallona, D.F. Stroup, U. Winkler, W. Gesierich, V. Diehl, J.O. Staak, P. Robben-Bathe, R. Abelius, C. Scheid, W.E. Berdel, T. Cerny, C. Kahl, J. Bernhard, S.M. Liesenfeld, P. Heusser, E. Dühmke, W. Hinkelbein, K. Dietzmann, A. Florschütz, J. Dannull, T. Kühn, E. von Rohr, S. Krege, C. Bausewein, D. Söhngen, A. Franke, D. Moher, H. Hollenhorst, I. Olkin, M. Fuchs, T.G. Wendt, J. Baumgart, U. Aydemir, U. Geiersberger, C. Hürny, D.J. Cook, G. Schaller, B. Schymura, D.K. Ackermann, B. van Wegberg, R. Munker, N. Bornfeld, M. Groettrup, P. Sevelda, K. Mross, H. Fiebig, N. Brack, E. Thiel, L. Edler, R. Kreienberg, A. Pfleiderer, N. v. Steinbüchel, C. Unger, S. Helwig, S. Sehlen, H. Pohlmann, K. Jentsch-Ullrich, R. Souchon, K.-M. Kreusel, D. Rennie, A. Engert, H.-J. Schmoll, and S. Schwartz

Subjects
Cancer Research, Oncology, Hematology
Published
2000

14. Band 23, Heft 2, April 2000

Author

D. Hoelzer, R. Pasold, J. Ströhl, F.A. Hoffmann, Ch. Armbruster, S.B. Sobottka, N. Runkel, C. Stöllberger, A. Böhme, S. Grützner, W. Knauf, Helmut Oettle, Hanno Riess, T. Wiegel, M. Brandis, J. Behrens, M. Freund, H. Lassmann, G. Schackert, M. Burian, T. Kühn, H. Wolf, K. Guhr, A. Steinmetz, Ü. Aydemir, M.P. Wirth, K. Rossa, A.U. Schratter-Sehn, R. Kreienberg, A. Gerl, M. Herold, H.-J. Hurtz, Marjanka K. Schmidt, M. Huber, C. Neuchrist, C. Santjohanser, G.-V. Kornek, E. Hiller, W. Hinkelbein, A. Manseck, M. Alfrink, O. Hakenberg, N. Willich, W. Schmidt, J. Kornfehl, A. Franke, K. Koretz, U. Duffner, Chr. Klinkenstein, C. Rübe, Wolf O. Bechstein, S. Palkovic, S. Hahnfeld, S. Höcht, M. Aßmann, W. Wagner, R. Munker, L. Meyer, D. Huhn, D. Hölzel, C.M. Niemeyer, H. Eschenburg, M. Kirsch, J. Steglich, and U. von Grünhagen

Subjects
Cancer Research, Oncology, Hematology
Published
2000

15. Band 23, Heft 6, Dezember 2000

Author

K. Mross, J. Dannull, K. Dietzmann, E. Thiel, R. Song, H. Schulz, S. Krege, N. Brack, V. Diehl, W.E. Berdel, T. Cerny, G. Schaller, N. v. Steinbüchel, P. Heusser, C. Bausewein, P. Robben-Bathe, T.G. Wendt, E. von Rohr, N. Bornfeld, U. Geiersberger, T. Wiegel, P. Sevelda, C. Hürny, S. Schwartz, A. Schulz, E. Dühmke, D. Bottke, S. Pampallona, W. Gesierich, D.J. Cook, J. Bernhard, U. Winkler, T. Kühn, A. Florschütz, K. Jentsch-Ullrich, R. Souchon, C. Scheid, S.M. Liesenfeld, D. Söhngen, K.-M. Kreusel, H. Pohlmann, C. Kahl, C. Unger, H. Hollenhorst, A. Krackhardt, R. Hartenstein, W. Hinkelbein, R. Abelius, J. Baumgart, I. Olkin, B. Schymura, S. Eastwood, M. Groettrup, M. Fuchs, A. Franke, U. Aydemir, J.O. Staak, D. Rennie, D.K. Ackermann, D. Moher, R. Munker, B. van Wegberg, D.F. Stroup, R. Kreienberg, L. Edler, A. Pfleiderer, A. Engert, H.-J. Schmoll, S. Helwig, S. Sehlen, and H. Fiebig

Subjects
Cancer Research, Oncology, Hematology
Published
2000

16. Locoregional High-Frequency Hyperthermia and Temperature Measurement

Author

G. Bruggmoser, W. Hinkelbein, R. Engelhardt, M. Wannenmacher, G. Bruggmoser, W. Hinkelbein, R. Engelhardt, and M. Wannenmacher

Subjects
Oncology, Radiology
Abstract

The present challenge in the treatment of tumors is to reduce the number of patients that still die as a result of primary tumors. Today, the percentage of such deaths remains high at 30%, even when all the common therapeutic methods, namely surgery, radiotherapy, and chemotherapy, are applied. In order to reduce this percentage, new types of radiation sources with a higher linear energy transfer have been intro­ duced, such as neutrons and pions. Fractionation patterns have been modified and radiosensitizers have been applied to in­ crease biological efficiency. Studies of the combined application of chemotherapy and radiotherapy have been made to find the best therapeutic effect. In the early 1970s biological findings confirmed the effect of hyperthermia on tumor cells. The first clinical studies on hyper­ thermia treatment demonstrated that it resulted in better local tumor control. Further application of this treatment modality showed that hyperthermia should be used in addition to radio­ therapy and chemotherapy. Despite these encouraging results, hyperthermia has not been introduced into common clinical use, due primarily to technical problems. There are a number of methods of transferring heat into tumors; however, with regard to physical conditions, an op­ timum method has not yet been found. One of the reasons is that up to now we have had no reliable method of obtaining thermal mapping of all parts of the human body. Such measurements are required not only for dosimetric purposes but also for the regula­ tion of a hyperthermic system.

Published
2012

18. Auswirkungen der Therapie von Larynx- und Hypopharynxkarzinomen auf die Funktion der Tuba Eustachii*

Author

B. Richter, Chl. Beck, W. Hinkelbein, and Wolfgang Maier

Subjects
Larynx, medicine.medical_specialty, animal structures, Percutaneous, business.industry, Eustachian tube, medicine.medical_treatment, Positive pressure, Neck dissection, Surgery, medicine.anatomical_structure, Otorhinolaryngology, Swallowing, Middle ear, Medicine, business, Complication
Abstract

In a prospective investigation Eustachian tube function was tested before and after surgery and irradiation of patients suffering from carcinoma of the larynx or hypopharynx. Passive and active tubal parameters were determined using the dual-impedance method in a pressure chamber. In this test, passive tubal function is described by the spontaneous opening and closing characteristics of the tube by an overpressure in the middle ear. Active tubal parameters are determined by the facility of the tube to equalize an over- and underpressure in the middle ear by swallowing. Statistic evaluation was performed with Student's t-test. There were no significant alterations of passive or active tubal function after neck dissection with or without surgery of the primary tumour. On the other hand we observed significant deterioration of all tubal parameters immediately after a series of fractionated percutaneous telecobalt therapy (60 Gy). 2 out of 18 patients developed unilateral middle ear effusion during irradiation which was reversible within 6 months. In most patients we observed a total or at least partial restitution of passive tubal parameters during this time, which was statistically significant. The active tubal function was of minor reversibility. Whereas the facility to equalize a positive pressure in the middle ear was quite good after 6 months, only few patients were able to equalize a negative pressure. The temporary deterioration of passive tubal function may be caused by a marginal implication of the tube at the edge of the irradiation field and by increased lymphatic pressure in tubal tissue following a radiogenic swelling of the lymphatic vessels of the neck.(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1994

19. Nutzen und Risiken der kombinierten Radiochemotherapie

Author

W. Hinkelbein

Subjects
Cancer Research, Oncology, Hematology
Abstract

Multimodale Behandlungskonzepte unter Einschluβ einer Strahlen- und Chemo-therapie bestimmen heute die Behandlung von malignen Lymphomen, kindlichen Neoplasien, Weichteilsarkomen und des kleinzelligen Bronchialkarzinoms. Daneben haben in den letzten Jahren kombinierte Radiochemotherapie-Konzepte bei soliden Tumoren zunehmend an Bedeutung gewonnen. Simultane Radiochemotherapien konnen das Schicksal von Patienten mit weit fortgeschrittenen Tumoren verbessern (z. B. Kopf-Hals-Region), verstummelnde Operationen vermeiden (z. B. Analkarzi-nom), die Lokalrezidivquote senken (z.B. Rektumkarzinom) und die Heilungsraten erhohen. Dafur ist eine erhohte Behandlungsmorbiditat in Kauf zu nehmen, sowohl wegen der zusatzlichen Nebenwirkungen der Chemotherapie als auch wegen einer Verstarkung der akuten Strahlenreaktion, die eine moderne supportive Therapie erfordern. Zur Vermeidung verstarkter Spatfolgen sind moglichst Substanzen zu verwenden, die keine spezifische Toxizitat an den Risikoorganen in der Bestrah-lungsregion haben, und die Einzeldosis pro Tag ist zu reduzieren. Die Behandlung soil nur nach vorgegebenen Protokollen erfolgen mit exakter Dokumentation aller Nebenwirkungen. Jahrelange Nachkontrolle zur Erfassung moglicher Spatfolgen ist erforderlich. Die Effektivitat neuer Radiochemotherapie-Konzepte muβ in rando-misierten Studien nachgewiesen werden. Bei Beachtung dieser Vorgaben konnen wir in den nachsten Jahren wahrscheinlich immer mehr Patienten mit soliden Tumoren helfen, ohne ihnen ein inadaquates Risiko aufzuburden.

Published
1994

20. Impressum / Inhalt, Vol. 17, 1994

Author

R. Hartenstein, Rainer Schmidt, W.M. Gallmeier, E. Schlick, S.K. Chan, U. Kalokhe, H. Kupper, Renate Muller-Runkel, H. Kappauf, Walther Kuhn, T. Rähn, Thomas Wiegel, F. Raue, M. Sääf, W. Zumkeller, Theodore Karrison, Howard J. Halpern, W. Hinkelbein, Harald Meden, U. Bartels, Srinivasan Vijayakumar, W. Rath, K. Pandya, P. Tsikuras, Daniel J. Haraf, J. Winter, A. Houghton, Steven J. Rubin, M. Bressel, Eckhart Dühmke, Harold G. Sutton, Azhar Awan, M. Busch, H. zur Hausen, G. Keilhauer, C. Romerdahl, G. Kaiser, W. Queißer, Ralph R. Weichselbaum, and S.F. Quadri

Subjects
Cancer Research, Oncology, Hematology
Published
1994

21. [Radiation therapy for prostate cancer in the new S3 guideline. Part 1: localized and locally advanced prostate cancer]

Author

D, Böhmer, F, Wenz, T, Martin, F, Sedlmayr, W, Hinkelbein, and T, Wiegel

Subjects
Male, Evidence-Based Medicine, Germany, Brachytherapy, Practice Guidelines as Topic, Disease Progression, Humans, Prostatic Neoplasms, Bone Neoplasms, Radiotherapy Dosage, Radioisotope Teletherapy, Disease-Free Survival, Neoplasm Staging
Abstract

Radiation therapy is a treatment option for curative management of localized and locally advanced prostate cancer. Depending on tumor stage and constellation of risk factors (PSA level, findings on digital rectal examination, and Gleason score), various forms of radiotherapy are applied. In addition to the sole use of external beam radiotherapy, brachytherapy with radioactive seeds is also employed as stand-alone treatment in patients with low risk factors and in early clinical stages. Increasing risk of recurrence requires more intensive therapies which can be accomplished by adding hormone deprivation therapy and/or intensifying radiation therapy (dose escalation). Combined approaches using brachytherapy and percutaneous radiotherapy are also initiated in these cases. If hormone ablation therapy is administered, this should occur over a course of 3-36 months as neoadjuvant, concommitant and/or adjuvant treatment, depending on the risk of recurrence.

Published
2010

22. [Radiation therapy for prostate cancer in the new S3 guideline. Part 2: postoperative radiation therapy and brachytherapy]

Author

T, Martin, F, Wenz, D, Böhmer, F, Sedlmayer, W, Hinkelbein, T O, Henkel, K, Miller, and T, Wiegel

Subjects
Male, Prostatectomy, Evidence-Based Medicine, Brachytherapy, Prostatic Neoplasms, Androgen Antagonists, Radiotherapy Dosage, Prostate-Specific Antigen, Combined Modality Therapy, Disease-Free Survival, Practice Guidelines as Topic, Biomarkers, Tumor, Disease Progression, Humans, Radiotherapy, Adjuvant, Neoplasm Staging, Randomized Controlled Trials as Topic
Abstract

Postoperative adjuvant radiation therapy has achieved special significance based on the results of three randomized studies on stage pT3R1 prostate cancer which provided evidence for prolonged survival in comparison to the "wait and see" strategy. When PSA levels persist or increase after radical prostatectomy, irradiation represents an alternative. In this instance, salvage radiotherapy should be initiated as early as possible, most suitably when the PSA level is0.5 ng/ml. Side effects of percutaneous radiotherapy using modern techniques are minimal in this stage; severe grade 3 or 4 late sequelae occur in3% of cases. Low dose rate (LDR) brachytherapy as monotherapy is a primary treatment option for low-risk tumors. In patients with intermediate-risk tumors, data are controversial and cannot be assessed conclusively. LDR brachytherapy should not be administered in high-risk tumors. High dose rate (HDR) brachytherapy combined with percutaneous radiotherapy as an example of a typical dose escalation approach is a primary option for intermediate- and high-risk prostate cancer. Whether additional hormone therapy is needed with HDR brachytherapy is unclear. HDR monotherapy can only be recommended in the clinical trial setting.

Published
2010

23. Experimental thermoradiotherapy of human tumour xenografts in nude mice; design of the hyperthermia system

Author

G. Bruggmoser, W. Hinkelbein, and R. Saum

Subjects
Hyperthermia, Cancer Research, Materials science, Thermometers, Physiology, Thermal dosimetry, Transplantation, Heterologous, Mice, Nude, Imaging phantom, Mice, Physiology (medical), medicine, Animals, Humans, Microwaves, Radiometry, Radiometer, business.industry, Temperature, Hyperthermia, Induced, Neoplasms, Experimental, medicine.disease, Combined Modality Therapy, Models, Structural, Evaluation Studies as Topic, Brightness temperature, Microwave radiometry, Nuclear medicine, business, Bolus (radiation therapy), Microwave, Neoplasm Transplantation
Abstract

An experimental thermoradiotherapy study was started in 1986. For this study a hyperthermia system was developed for the heating of human tumours xenotransplanted into nude mice. Our treatment device was a four-channel computer-controlled hyperthermia system. Temperature was monitored by microwave radiometry at 3 GHz. Specifications of the radiometer were first evaluated under reference conditions, then thermal dosimetry was studied using non-invasive measurement of the brightness temperature TOR. Hyperthermia treatments were simulated in phantom material with radiometric monitor values TR of 40 and 41. In conjunction with the parameters of brightness temperature TOR, surface temperature TO and water bolus temperature TW thermal modelling was performed. Finally, we studied the influence of a perfused phantom to the microwave thermometry.

Published
1992

24. Title Page / List of Contents

Author

A. Schmittel, J. Heide, W. Hinkelbein, and D. Kaiser

Subjects
business.industry, Medicine, Library science, Title page, business
Published
2009

25. Controversies in the Treatment of Prostate Cancer

Author

L. Moser, M. Schostak, W. Hinkelbein, and Kurt Miller

Subjects
Radiation therapy, Gerontology, medicine.medical_specialty, Prostate cancer, business.industry, medicine.medical_treatment, General surgery, medicine, business, medicine.disease
Published
2008

26. Role of Thoracic Radiotherapy Combined with Chemotherapy in Limited Stage Small Cell Lung Cancer (SCLC)

Author

Th. Zwingers, W. Hinkelbein, A. Kraft, M. Wannenmacher, F. v. Bültzingslöwen, H. Bodemann, and H. Arnold

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Thoracic radiotherapy, Limited stage small cell lung cancer, Hematology, medicine.disease, Primary tumor, law.invention, Radiation therapy, Randomized controlled trial, law, Internal medicine, Multicenter trial, medicine, Small cell lung cancer stage, business
Abstract

We initiated a prospective randomized multicenter trial to clarify the role of radiotherapy in the treatment of the primary tumor in small cell lung cancer stage limited disease. Patients were randomi

Published
1990

27. Contents

Author

J.L. Meyer and W. Hinkelbein

Published
2007

29. Controversies in the Treatment of Skin Neoplasias

Author

W. Hinkelbein, T. Wiegel, C.E. Orfanos, M. Sternemann, and C.C. Geilen

Subjects
Radiation therapy, medicine.medical_specialty, business.industry, medicine.medical_treatment, General surgery, medicine, Physiology, business
Published
2005

31. The Role of Radiotherapy in the Management of Malignant Melanoma

Author

S. Marnitz, S. Hoecht, and W. Hinkelbein

Subjects
Radiation therapy, Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine.medical_treatment, Melanoma, MEDLINE, Medicine, business, medicine.disease, Dermatology, Malignant transformation
Published
2005

32. 182 Development and internal validation of a nomogram predicting biochemical recurrence after early salvage radiotherapy in prostate cancer patients treated with radical prostatectomy

Author

Marco Bianchi, Alberto Briganti, Nazareno Suardi, Karin Haustermans, Bertrand Tombal, Thomas Wiegel, Nadia Di Muzio, Steven Joniau, W. Hinkelbein, Van Poppel Hein, Francesco Montorsi, and Cesare Cozzarini

Subjects
Oncology, Biochemical recurrence, medicine.medical_specialty, business.industry, Prostatectomy, Proportional hazards model, Urology, medicine.medical_treatment, Nomogram, urologic and male genital diseases, medicine.disease, Radiation therapy, Prostate cancer, medicine.anatomical_structure, Prostate, Internal medicine, medicine, Stage (cooking), business
Abstract

INTRODUCTION AND OBJECTIVES: Previous studies have shown that the efficacy of salvage radiotherapy (SRT) in men with biochemical recurrence (BCR) after radical prostatectomy (RP) is strongly related to PSA value at SRT. Contemporary guidelines suggest that SRT,when indicated, should be given at a PSA 0.5 ng/ml (early SRT eSRT). Such approach might be comparable in terms of cancer control to adjuvant RT while significantly reducing the number of patients exposed to RT. However, there is no available model for the prediction of BCR after eSRT. We developed and internally validated a model predicting BCR in patients treated with eSRT after RP for PCa METHODS: The study included 342 patients who received eSRT for BCR after RP at 6 European tertiary care centers between 1993 and 2006. Early SRT was defined as a salvage treatment given at a PSA 0.5 ng/ml. All patients had pT3, pN0, / positive surgical margins (SM). BCR after RP and eSRT was defined as two consecutive PSA values 0.2 ng/mL. No patient received adjuvant hormonal therapy. Radiotherapy consisted of a local radiation delivered to the prostate and seminal vesicle bed alone. Univariable (UVA) and multivariable (MVA) Cox regression models predicting BCR after eSRT were fitted. Predictors consisted of PSA at eSRT, time from RP to BCR, SM status, pT stage, radiotherapy dose and pathological Gleason score (6 vs. 7 vs. 8 or more). Regression-based coefficients were then used to develop a nomogram predicting BCR at 5 years after eSRT. The accuracy of the nomogram was quantified with the Harrel’s concordance index and the calibration plot method. Two hundred bootstrap resamples were used for internal validation. RESULTS: Mean follow-up was 81 months (median 68 months). Mean RT dose was 68 Gy (median 66.6 Gy,range:60-75.6 Gy). BCR-free survival rates at 2, 5 and 8 years after eSRT were 78.4, 61.5 and 56.8%, respectively. At univariable Cox regression analyses, pathological Gleason sum, PSA at eSRT and SM status were indipendent predictors of BCR after eSRT (all p 0.005). The results were confirmed at MVA where all mentioned predictors, including PSA at eSRT, were significantly associated with BCR after eSRT (all p 0.004). The coefficient-based nomogram demonstrated a bootstrapcorrected predictive accuracy of 74.7%. CONCLUSIONS: More than half of patients treated with eSRT for BCR after surgery had undetectable PSA at 5 years. We report the first nomogram predicting BCR in these patients. Our model might be used to assess the impact of eSRT according to each individual characteristics. Source of Funding: None

Published
2013

34. Controversies in Gastrointestinal Tumor Therapy

Author

T. Wiegel, M. Sternemann, S. Hcht, W. Hinkelbein, and H.J. Buhr

Subjects
Radiation therapy, medicine.medical_specialty, Gastrointestinal tumors, business.industry, General surgery, medicine.medical_treatment, medicine, Physiology, business
Published
2004

36. Intraoperative Strahlentherapie des Magenkarzinoms

Author

W. Hinkelbein and T. Wiegel

Abstract

➲ Die Ergebnisse der multimodalen Therapie des Magenkarzinoms sind weiterhin unbefriedigend. Einerseits stellt nach kurativer Gastrektomie und ausgedehnter Lymphknotendissektion das Lokalrezidiv je nach Tumorstadium in 35–80% ein erhebliches onkologisches Problem dar, andererseits ist der Tumor zu diesem Zeitpunkt bereits haufig disseminiert (Bruwer et al. 2000).

Published
2004

37. Schwere Neuropathie nach Chemo- und Radiotherapie eines Ewing-Sarkoms

Author

S. Sauter, Charlotte M. Niemeyer, R. Korinthenberg, W. Hinkelbein, and Christian Lilje

Subjects
Chemotherapy, medicine.medical_specialty, business.industry, medicine.medical_treatment, medicine.disease, Treatment side effects, Surgery, Radiation therapy, Lumbar, Peripheral neuropathy, Pediatrics, Perinatology and Child Health, Medicine, Lumbar spine, Sarcoma, business, Complication
Abstract

A 15 year old patient presenting with a lumbar Ewing's Sarcoma was treated according to the EICESS-92 pilot study (EVAIA branch). Local therapy consisted of definitive irradiation given simultaneously to chemotherapy courses 5 to 7. Close to the end of treatment the patient developed progressive peripheral neurologic deficits. Such combined toxic treatment side effects are unique and unforeseen in the study protocol.

Published
1995

39. Implantable cardiac defibrillators may be damaged by radiation therapy

Author

S. Hoecht, P. Rosenthal, D. Sancar, S. Behrens, W. Hinkelbein, and U. Hoeller

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiotherapy, business.industry, MEDLINE, medicine.disease, Defibrillators, Implantable, Thalidomide, Tumor lysis syndrome, Text mining, Internal medicine, medicine, Humans, Equipment Failure, business, Multiple myeloma, medicine.drug
Published
2002

41. Interstitial brachytherapy with permanent seed implants in early prostate cancer

Author

U, Maurer, Th, Wiegel, W, Hinkelbein, and M J, Eble

Subjects
Drug Implants, Male, Brachytherapy, Prostatic Neoplasms, Adenocarcinoma, Prostate-Specific Antigen, Disease-Free Survival, Iodine Radioisotopes, Treatment Outcome, Antigens, Neoplasm, Biomarkers, Tumor, Humans, Radiopharmaceuticals, Radiation Injuries
Abstract

Excellent clinical results after permanent seed implantation have been reported by various centers in large cohorts of patients. However, all of these had extensive experience in this special field of radiotherapy and the therepy and the follow-up time is too short for definite conclusions. The fact that this option of treatment can be carried out on an outpatient basis and that it allows to get the patient back to normal as far as social environment and work are concerned, has led to wide acceptance of this particular mode of therapy. Therefore, permanent seed implantation is a possible treatment option for localized prostate cancer and can be offered to patients with T1- T2a tumors, PSA levels of10 and a Gleason score of7. By using permanent seed implantation in these selected patients, it seems possible to achieve results comparable with surgery alone or percutaneous, 3D-planned radiotherapy.

Published
2002

42. Controversies in Uro-Oncology

Author

Rüdiger Heicappell, T. Wiegel, W. Hinkelbein, and Kurt Miller

Subjects
Radiation therapy, medicine.medical_specialty, business.industry, medicine.medical_treatment, Regional science, Medicine, Medical physics, business
Published
2002

45. [Osteoradionecrosis after radiotherapy for gynecologic tumors]

Author

U, Höller, S, Hoecht, E, Wudel, and W, Hinkelbein

Subjects
Aged, 80 and over, Time Factors, Radiotherapy, Genital Neoplasms, Female, Pain, Middle Aged, Diagnosis, Differential, Fractures, Bone, Osteoradionecrosis, Humans, Female, Pelvic Bones, Tomography, X-Ray Computed, Osteoporosis, Postmenopausal, Aged
Abstract

Insufficiency fractures of the pelvis are a well known but rare and frequently misinterpreted radiation sequela. The clinical features and possible risk factors were investigated.71 of living 82 patients, who were treated 1986-1994 for gynecologic tumors were clinically examined. 47 patients underwent also bone scan, CT of the pelvis and 13 patients had osteodensitometry. All patients had been treated with adjuvant (n = 29) or curative intent (n = 18) by d.v. fields with 18-MV photons, with 46 Gy in 23 fractions plus brachytherapy (15-39 Gy). Median follow-up was 36 months.Seven patients developed pelvic insufficiency fractures 11 months (median, minimum 2 months) after treatment. All patients complained of moderate to severe pelvic pain, which resolved after 5-28 months without specific therapy in five of seven patients. At first examination all but one bone scan showed extremely increased uptake in the os sacrum and/or iliosacral joints, correlating CT scans demonstrated small fractures and bony destruction. Four of the asymptomatic 40 patients with complete radiologic examinations had medium uptake in bone scan (CT normal). Three of four examined patients with insufficiency fractures and seven of nine patients without insufficiency fractures had osteoporosis.In women who present with pelvic pain after radiotherapy for gynecologic tumors bony destruction and fractures may be indicative of a late radiation effect rather than osseous metastasis, even after early onset of symptoms.

Published
2001

46. [Radiotherapeutic strategies in the multimodal therapy of resectable and nonresectable pancreatic carcinoma]

Author

T, Wiegel, N, Runkel, H, Frommhold, C, Rübe, and W, Hinkelbein

Subjects
Pancreatic Neoplasms, Chemotherapy, Adjuvant, Humans, Prognosis, Combined Modality Therapy
Abstract

The prognosis of patients with adenocarcinoma of the pancreas remains poor. Only patients with small tumors and complete resection have a curative chance. The value of combined radio-chemotherapy adjuvant or even palliative in case of unresectable tumors is controversial due to the short median survival times of all patients ranging from 8 to 15 months. Within the last years, significant new treatment modalities were introduced into the multimodality approach. Even the intraoperative boost therapy (IORT) with fast electrons remains still controversial.Since the publication of the results of the historic GITSG study, in the US postoperative adjuvant radio-chemotherapy with 5-FU remains the treatment of choice. Successor studies of the ESPAC and the EORTC have been closed or are recruiting patients, the results are still pending. Neoadjuvant treatment modalities were investigated within the last 3 years, mostly in case of primary operable but also in unresectable tumors. Using 3-D-treatment planning, the total dose of radiotherapy was increased from 40 up to 45 to 50 Gy. In centers with great experience, an IORT was added to these combined modalities. More modern chemotherapeutic agents like gemcitabine or the taxanes are under investigation, using combined radio-chemotherapy in phase-II protocols in patients with unresectable tumors.In case of both, adjuvant or neoadjuvant radio-chemotherapy following or before pancreaticoduodenectomy, median survival times range from 15 to 25 months. The neoadjuvant radio-chemotherapy seems to reduce the rate of positive surgical margins and the rate of patients with positive lymph nodes. For the moment, there is no proven survival advantage or increase of local control (about 80% in both cases) for patients treated with neoadjuvant radio-chemotherapy compared with adjuvant radio-chemotherapy. However, about 25% of the patients don't receive adjuvant therapy due to the perioperative morbidity. Because prolongation of survival with adjuvant therapy is only 5 to 10 months, in Europe adjuvant radio-chemotherapy is not accepted as the treatment standard. Combined radio-chemotherapy in patients with unresectable tumors results in significant improvement of survival. 5-FU continuous infusion with 250 mg/m2 seems to be the treatment of choice. IORT is effective in achieving long-term local control and an effective pain palliation. More modern chemotherapeutic agents seem to be effective in vitro as radio-sensitizers. In first reported results, the MTD was not found. Toxicity seems not to be increased with single radiotherapy doses of 1.8 to 2 Gy. However, higher single doses should not be used.Due to the worse prognosis of patients with adenocarcinoma of the pancreas, new combined treatment modalities as adjuvant and neoadjuvant radio-chemotherapy, particularly with more modern chemotherapeutic agents, for patients with resectable and unresectable tumors are under investigation. For some reasons, the neoadjuvant setting seems to be better. However, these results are not proven by prospective randomized clinical trials. Therefore, these trials are necessary to define the treatment of choice in these patients. IORT is a helpful tool to improve local control. However, these aggressive multimodality approaches are only indicated in a minority of patients. In patients with unresectable tumors and good condition, combined radio-chemotherapy remains the treatment of choice.

Published
2000

49. Strahlentherapeutische Optionen nach radikaler Prostatektomie

Author

T. Wiegel and W. Hinkelbein

Abstract

Nach der radikalen Prostatektomie, die in den USA nur in den klinischen Stadien T1-2 routinemasig eingesetzt wird, ist postoperativ bei T1/2a-Karzinomen in bis zu 25% der Falle ein pathologisches Stadium T3/4 nachweisbar; diese Wahrscheinlichkeit steigt bei einem klinischen T2b-c-Tumor auf uber 40% [8,9]. In Deutschland werden haufig auch Patienten mit klinischen T3-Karzinomem radikal prostatektomiert. Bei diesen Stadien liegt die Wahrscheinlichkeit eines postoperativ organuberschreitenden Tumorwachstums wegen der erheblichen praoperativen Stagingunsicherheiten bei 70–80% [9,21].

Published
1999

Catalog

Books, media, physical & digital resources
See catalog results